COVID-19 Paediatric VLA2001-321 Study

Summary

This is a Randomized, Double-blinded, Active-controlled Study to evaluate the Safety, Tolerability and Immunogenicity of VLA2001 in participants of ≥2 to 12 years. In total 1720 participants will receive either VLA2001 or active Comparator.

Timeline

Start

2022-10-01

Primary completion

2023-07-31

Completion

2025-08-30

Outcome

Outcome not reported

Stopped: “Valneva has contacted regulators to align on potential adjustments to the previously agreed Pediatric Investigational Plan. Valneva has suspended VLA2001 pediatric development, and study VLA2001-321 will not commence.”

Drugs

Indications